Titan Pharmaceuticals Inc. (TTNP)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Titan Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CAL CoreCap Advisors LLC CoreCap Advisors LLC | 88 | $310.64 | $205.92 | -$104.72 | -33.71% |
 Christopher C. Powers Farther Finance Advisors, LLC | 1 | $1 | $2.34 | $1.34 | 134% |
Titan Pharmaceuticals Inc. (TTNP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Titan Pharmaceuticals Inc. ever had a stock split?
Titan Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Weei Jye Chay CEO | NASDAQ (CM) Exchange | 888314606 CUSIP |
| KY Country | 4 Employees | 1 Dec 2020 Last Dividend | 9 Jan 2024 Last Split | 18 Jan 1996 IPO Date |
Overview
Titan Pharmaceuticals, Inc. is a distinguished entity in the pharmaceutical sector, primarily focused on the development of innovative therapeutics aimed at the treatment of chronic diseases. The foundation of its product development strategy is the ProNeura technology, a proprietary long-term drug delivery platform that represents a pioneering step forward in the sustained release of medications. Established in 1992, Titan Pharmaceuticals has cemented its presence in the pharmaceutical landscape, operating from its base in South San Francisco, California. The company's mission encapsulates the commitment to leveraging its proprietary technology to improve patient outcomes in various chronic conditions, underscoring Titan's role in addressing some of the most pressing healthcare challenges globally.
Products and Services
- Probuphine Implant
A novel approach to the maintenance treatment of opioid use disorder, the Probuphine implant utilizes Titan's cutting-edge ProNeura technology to deliver a continuous, low-dose treatment for clinically stable patients. This product is notably available in Canada and the European Union, offering a discreet and convenient option for patients striving to manage their condition.
- Kappa Opioid Agonist Peptide Program (TP-2021)
Currently under development, this program represents an ambitious endeavor to harness the potential of ProNeura technology in treating chronic pruritus. The TP-2021 program aims to develop a kappa opioid agonist peptide that, when used in conjunction with ProNeura, could offer a long-term solution for patients suffering from this debilitating condition.
- Nalmefene Implant Program
This innovative program focuses on the prevention of opioid relapse following the detoxification process in patients battling opioid use disorder. By providing a sustained release of nalmefene via an implant, Titan Pharmaceuticals seeks to offer a groundbreaking tool in the fight against the opioid epidemic, targeting one of the most critical stages of recovery.
- Other Programs
Expanding its application of ProNeura technology, Titan Pharmaceuticals is also exploring its use in other critical areas of healthcare. These include the development of a HIV preventative therapeutic and a contraceptive implant capable of offering long-term protection for women and adolescent girls. This diversification of applications underscores the versatility and potential of ProNeura technology in contributing to global health solutions.
